Use of chitosan in compressed tablets of diclofenac sodium: Inhibition of drug release in an acidic environment

Pharmaceutical Development and Technology

Volumn 2, Issue 3, 1997, Pages 243-255

  Sabnis, Shobhan ^a   Rege, Pankaj ^a   Block, Lawrence H ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

Biodegradable polymer; Chitosan; pH dependent release; Polyelectrolyte; Polyionic complex

Indexed keywords

CHITOSAN; DICLOFENAC; POLYELECTROLYTE; POLYMER;

ARTICLE; DEACETYLATION; DIGESTIVE SYSTEM INJURY; DRUG RELEASE; DRUG SOLUBILITY; INFLAMMATION; IONIC STRENGTH; PH; PRIORITY JOURNAL; TABLET COMPRESSION; TABLET FORMULATION;

EID: 0031390929     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.3109/10837459709031444     Document Type: Article

References (23)

1. W. M. O'Brien, Adverse reactions to nonsteroidal anti-inflammatory drugs: Diclofenac compared with other nonsteroidal anti-inflammatory drugs, Am. J. Med., 80 (suppl. 4B), 70-80 (1986).
2. R. N. Brogden, R. C. Heel, G. E. Pakes, T. M. Speight, and G. S. Avery, Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin, Drugs, 20, 24-48 (1980).
3. Y. Sawayanagi, N. Nambu, and T. Nagai, Directly compressed tablets containing chitin or chitosan in addition to lactose or potato starch, Chem. Pharm. Bull., 30, 2935-2940 (1982).
4. F. Acartürk, Preparation of a prolonged-release tablet formulation of diclofenac sodium, part 1: using chitosan, Pharmazie, 44, 547-547 (1989).
5. A. Nigalaye, P. Adusumilli and S. Bolton, Investigation of prolonged drug release from matrix formulations of chitosan, Drug Dev. Ind. Pharm., 16, 449-467 (1990).
6. J. Knapczyk, Excipient ability of chitosan for direct tableting, Int. J. Pharm., 89, 1-7 (1993).
7. A. A. Al-Angary, Effects of molecular weight and particle size of chitosan on chlorpheniramine maleate release from compressed tablets, Saudi Pharm. J., 2, 157-162 (1994).
8. P. R. Austin and C. J. Brine, Chitin powder and process for making it, U.S. patent # 4,286,087, August 25, 1981.
9. H. J. Dunn and M. P. Farr, Microcrystalline chitin, U. S. patent # 3,847,897, November 12, 1974.
10. S. Shiraishi, M. Arahira, T. Imai, and M. Otagiri, Enhancement of dissolution rates of several drugs by low-molecular chitosan and alginate, Chem. Pharm. Bull., 38, 185-187 (1990).
11. T. Imai, S. Shiraishi, H. Saitô, and M. Otagiri, Interaction of indomethacin with low molecular weight chitosan, and improvements of some pharmaceutical properties of indomethacin by low molecular weight chitosans, Int. J. Pharm., 67, 11-20 (1991).
12. N. Errington, S. E. Harding, K. M. Vårum, and L. Ilium, Hydrodynamic characterization of chitosans varying in degree of acetylation, Int. J. Biol. Macromol., 15, 113-117 (1993).
13. S. S. Sabnis and L. H. Block, to be published.
14. S. S. Sabnis, Development of modified chitosans as excipients for use in drug delivery systems, Ph.D. dissertation, Duquesne University, 1996, pp. 63-72; cf. S. S. Sabnis and L. H. Block, Evaluation of the degree of N-deacetylation of chitosan using UV/VIS, IR, and NIR spectroscopic techniques, Pharm. Res., 11 (supp. 10), 31 (1994).
15. S. S. Sabnis, Development of modified chitosans as excipients for use in drug delivery systems, Ph.D. dissertation, Duquesne University, 1996, pp. 63-72; cf. S. S. Sabnis and L. H. Block, Evaluation of the degree of N-deacetylation of chitosan using UV/VIS, IR, and NIR spectroscopic techniques, Pharm. Res., 11 (supp. 10), 31 (1994).
16. L. H. Block and R. N. Patel, Solubility and dissolution of triamcinolone acetonide, J. Pharm. Sci. 62, 617-621 (1973).
17. S. Aiba, Studies on chitosan: 3. Evidence for the presence of random and block copolymer structures in partially N-deacetylated chitosans, Int. J. Biol. Macromol., 13, 40-44 (1991).
18. M. Hasegawa, A. Isogai, F. Onabe, M. Usuda, and R. H. Atalla, Characterization of cellulose-chitosan blend films, J. Appl. Polym. Sci., 45, 1873-1879 (1992).
19. File no. 26-921. Powder Diffraction File, JCPDS-International Center for Diffraction Data, Pennsylvania, 1986, pp. 367.
20. A. Fini, V. Zecchi, and A. Tartarini, Dissolution profiles of NSAID carboxylic acids and their salts with different counterions, Pharm. Acta Helv., 60, 58-62 (1985).
21. C. Larsen and H. Bundgaard, Kinetics of the acid-catalyzed cyclization of diclofenac to an indolinone in aqueous solution, Arch. Pharm. Chemi, Sci. Ed., 8, 100-108 (1980).
22. R. E. Gordon, T. W. Rosanske, D. E. Fonner, N. R. Anderson, and G. S. Banker, Granulation technology and tablet characterization, in Pharmaceutical Dosage Forms: Tablets, vol. 2 (H. A. Liebermann, L. Lachman, and J. B. Schwartz, eds.), Marcel Dekker, Inc., New York, 1990, pp. 245-348.
23. D. Hariharan and N. A. Peppas, Modelling of water transport and solute release in physiologically sensitive gels, J. Control. Rel., 23, 123-136 (1993).